JP2009518441A - Ｃｄ４０結合剤の使用方法 - Google Patents

Ｃｄ４０結合剤の使用方法 Download PDF

Info

Publication number
JP2009518441A
JP2009518441A JP2008544586A JP2008544586A JP2009518441A JP 2009518441 A JP2009518441 A JP 2009518441A JP 2008544586 A JP2008544586 A JP 2008544586A JP 2008544586 A JP2008544586 A JP 2008544586A JP 2009518441 A JP2009518441 A JP 2009518441A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
variable domain
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008544586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518441A5 (enExample
Inventor
ドラクマン，ジョナサン
ロウ，チェ−レオン
ルイス，ティム
Original Assignee
シアトル ジェネティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティクス，インコーポレーテッド filed Critical シアトル ジェネティクス，インコーポレーテッド
Publication of JP2009518441A publication Critical patent/JP2009518441A/ja
Publication of JP2009518441A5 publication Critical patent/JP2009518441A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008544586A 2005-12-09 2006-12-11 Ｃｄ４０結合剤の使用方法 Pending JP2009518441A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74924605P 2005-12-09 2005-12-09
US81135306P 2006-06-05 2006-06-05
US81130106P 2006-06-05 2006-06-05
US84723406P 2006-09-25 2006-09-25
PCT/US2006/047308 WO2007075326A2 (en) 2005-12-09 2006-12-11 Methods of using cd40 binding agents

Publications (2)

Publication Number Publication Date
JP2009518441A true JP2009518441A (ja) 2009-05-07
JP2009518441A5 JP2009518441A5 (enExample) 2010-01-21

Family

ID=38218421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008544586A Pending JP2009518441A (ja) 2005-12-09 2006-12-11 Ｃｄ４０結合剤の使用方法

Country Status (11)

Country Link
US (1) US20090304687A1 (enExample)
EP (1) EP1968636A4 (enExample)
JP (1) JP2009518441A (enExample)
KR (1) KR20080079301A (enExample)
AU (1) AU2006329944A1 (enExample)
BR (1) BRPI0619586A2 (enExample)
CA (1) CA2632698A1 (enExample)
IL (1) IL191990A0 (enExample)
MX (1) MX2008007140A (enExample)
NO (1) NO20083002L (enExample)
WO (1) WO2007075326A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533853A (ja) * 2012-10-30 2015-11-26 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CN101970003A (zh) * 2007-11-09 2011-02-09 诺华有限公司 抗cd40抗体的应用
EP2245065A1 (en) 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
HUE054075T2 (hu) * 2014-10-29 2021-08-30 Seagen Inc CD40 elleni nem fukozilált antitestek adagolása és bevitele
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HUE056769T2 (hu) * 2015-09-04 2022-03-28 Primatope Therapeutics Inc Humanizált anti-CD40 antitestek és felhasználásuk
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022266496A1 (en) * 2021-06-17 2022-12-22 Parker Institute For Cancer Immunotherapy Methods of treating kras mutation subtypes with cd40 agonist
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
ES2364816T3 (es) * 2001-04-02 2011-09-14 Genentech, Inc. Terapia de combinación.
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2005115453A2 (en) * 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
SG173322A1 (en) * 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
EP1885399B1 (en) * 2005-05-26 2010-10-20 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012017864; Ｈｕｓｓｅｉｎ　ＭＡ，　ｅｔ　ａｌ．: 'Ａ　ｐｈａｓｅ　Ｉ　ｈｕｍａｎｉｚｅｄ　ａｎｔｉ-ＣＤ４０　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｙ　（ＳＧＮ-４０）　ｉｎ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｍｕｌｔｉｐｌｅ　ｍｙｅｌｏｍａ' Ｂｌｏｏｄ Ｖｏｌ．１０６，　Ｎｏ．１１, 20051116, ｐ．７２３ａ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533853A (ja) * 2012-10-30 2015-11-26 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP2022191360A (ja) * 2012-10-30 2022-12-27 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP7482184B2 (ja) 2012-10-30 2024-05-13 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP2024096245A (ja) * 2012-10-30 2024-07-12 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP7698352B2 (ja) 2012-10-30 2025-06-25 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法

Also Published As

Publication number Publication date
AU2006329944A1 (en) 2007-07-05
IL191990A0 (en) 2008-12-29
NO20083002L (no) 2008-08-14
CA2632698A1 (en) 2007-07-05
MX2008007140A (es) 2009-03-04
BRPI0619586A2 (pt) 2018-08-28
EP1968636A4 (en) 2010-06-02
EP1968636A2 (en) 2008-09-17
US20090304687A1 (en) 2009-12-10
KR20080079301A (ko) 2008-08-29
WO2007075326A3 (en) 2008-09-04
WO2007075326A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
US20090304687A1 (en) Methods of using cd40 binding agents
JP7641323B2 (ja) 治療抗体およびその使用
US20220153857A1 (en) Anti-cd40 antibodies
US11279764B2 (en) Antibodies specific for epidermal growth factor receptor variant III and their uses
US8492531B2 (en) Nucleic acids encoding humanized anti-CD40 antibodies
RU2313368C2 (ru) Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
JP4679035B2 (ja) 併用療法
JP5122441B2 (ja) ヒト化抗ｃｄ７０結合剤およびその使用
CN112334195A (zh) 用于治疗自身免疫性疾病的抗cd40抗体
JP2023542678A (ja) 炎症状態の処置のための抗ｃｄ４０抗体の使用。
WO2024050031A2 (en) Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads
CN116782931A (zh) 抗cd40抗体用于治疗炎症性病况的用途
HK40017145A (en) Anti-gitr antibodies and methods of use thereof
HK1239706B (en) Anti-cd40 antibodies
HK1178176A (zh) 抗-cd40抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121023